Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)Jacques Bernier, Jean Louis Lefèbvre, Jay S. Cooper et al.|Head & Neck|2005Cited by 1.8k
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialAxel Le Cesne, Ole S. Nielsen, Jean‐Yves Blay et al.|Journal of Clinical Oncology|2005Cited by 421
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsPiotr Rutkowski, Scott M. Schuetze, Peter Hohenberger et al.|Journal of Clinical Oncology|2010Cited by 401
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupAxel Le Cesne, Jaap Verweij, Ian Judson et al.|Journal of Clinical Oncology|2000Cited by 258
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomasStefan Sleijfer, Jean‐Yves Blay, M. Ouali et al.|European Journal of Cancer|2009Cited by 246